A Successful Treatment Approach in 2 Patients With Type 1 Plasminogen Deficiency: Intratracheal Application of Fresh Frozen Plasma and Tissue Plasminogen Activator.


Journal

Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928

Informations de publication

Date de publication:
01 10 2023
Historique:
received: 04 02 2023
accepted: 18 04 2023
medline: 28 9 2023
pubmed: 25 7 2023
entrez: 25 7 2023
Statut: ppublish

Résumé

Respiratory system involvement is common in congenital plasminogen deficiency. Although many treatment approaches have been tried, there is still no definitive treatment for respiratory system involvement. We report 2 congenital plasminogen deficiency cases, who presented with severe respiratory symptoms, for whom a novel treatment modality was tried. After intravenous administration of FFP (fresh frozen plasma), tissue plasminogen activator and FFP were administered intratracheally, and respiratory system findings improved. Intratracheal administration of tissue plasminogen activator and FFP is an available treatment modality for patients with lung involvement. Fibrin plaques should be carefully removed and new lesion formation should be prevented.

Sections du résumé

BACKGROUND
Respiratory system involvement is common in congenital plasminogen deficiency. Although many treatment approaches have been tried, there is still no definitive treatment for respiratory system involvement.
OBSERVATIONS
We report 2 congenital plasminogen deficiency cases, who presented with severe respiratory symptoms, for whom a novel treatment modality was tried. After intravenous administration of FFP (fresh frozen plasma), tissue plasminogen activator and FFP were administered intratracheally, and respiratory system findings improved.
CONCLUSIONS
Intratracheal administration of tissue plasminogen activator and FFP is an available treatment modality for patients with lung involvement. Fibrin plaques should be carefully removed and new lesion formation should be prevented.

Identifiants

pubmed: 37490638
doi: 10.1097/MPH.0000000000002698
pii: 00043426-990000000-00246
doi:

Substances chimiques

Tissue Plasminogen Activator EC 3.4.21.68
Plasminogen 9001-91-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-426

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Shapiro AD, Menegatti M, Palla R, et al. An plasminogen international deficiency registry (HISTORY) of patients with. Haematologica. 2020;105:554–561.
Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia. 2008;14:1261–1268.
Schuster V, Hügle B, Tefs K. Plasminogen deficiency. J Thromb Haemost. 2007;5:2315–2322.
Celkan T. Plasminogen deficiency. J Thromb Thrombolysis. 2017;43:132–138.
Özçelik U, Akçören Z, Anadol D, et al. Pulmonary involvement in a child with ligneous conjunctivitis and homozygous type I plasminogen deficiency. Pediatr Pulmonol. 2001;32:179–183.
Firat T. Ligneous conjunctivitis. Am J Ophthalmol. 1974;78:679–688.
Hangül M, Tuzuner A, Somekh I, et al. Type 1 plasminogen deficiency with pulmonary involvement. J Pediatr Hematol Oncol. 2021;43:558–560.
Kilinc AA, Tarcin G, Kurugoglu S, et al. A novel combined treatment for plasminogen deficiency with lung involvement. Pediatr Pulmonol. 2020;55:E1–E3.
Cohen J, Cohen S, Cymberknoh MC, et al. Laryngeal obstruction in congenital plasminogen deficiency. Pediatr Pulmonol. 2012;47:923–925.
Aoki N, Moroi M, Sakata Y, et al. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest. 1978;61:1186–1195.
Martin-Fernandez L, Marco P, Corrales I, et al. The unravelling of the genetic architecture of plasminogen deficiency and its relation to thrombotic disease. Sci Rep. 2016;6:39255.
Kizilocak H, Ozdemir N, Dikme G, et al. Treatment of plasminogen deficiency patients with fresh frozen plasma. Pediatr Blood Cancer. 2018;65:1–4.
Schuster V, Seregard S. Ligneous conjunctivitis. Surv Ophthalmol. 2003;48:369–388.
Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood. 2006;108:3021–3026.
Kuehn BM. First treatment for plasminogen deficiency is approved. JAMA. 2021;326:379.
Shapiro AD, Nakar C, Parker JM, et al. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. 2018;131:1301–1310.

Auteurs

Serdar Al (S)

Departments of Pediatric Allergy and Immunology.

Oktay Ulusoy (O)

Pediatric Surgery, Dokuz Eylul University Medical Faculty, İzmir.

Suna Asilsoy (S)

Departments of Pediatric Allergy and Immunology.

Nevin Uzuner (N)

Departments of Pediatric Allergy and Immunology.

Ozge Kangalli (O)

Departments of Pediatric Allergy and Immunology.

Ozge Atay (O)

Departments of Pediatric Allergy and Immunology.

Isik Odaman Al (I)

Department of Pediatric Hematology and Oncology, Istanbul Medipol University, Medical Faculty, Istanbul, Turkey.

Oguz Ates (O)

Pediatric Surgery, Dokuz Eylul University Medical Faculty, İzmir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH